- Home
- PHUN vs CUE Comparison
PHUN vs CUE Comparison
Compare PHUN & CUE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PHUN
- CUE
- Stock Information
- Founded
- PHUN 2009
- CUE 2014
- Country
- PHUN United States
- CUE United States
- Employees
- PHUN N/A
- CUE N/A
- Industry
- PHUN EDP Services
- CUE Biotechnology: Pharmaceutical Preparations
- Sector
- PHUN Technology
- CUE Health Care
- Exchange
- PHUN Nasdaq
- CUE Nasdaq
- Market Cap
- PHUN 89.7M
- CUE 77.3M
- IPO Year
- PHUN N/A
- CUE 2018
- Fundamental
- Price
- PHUN $5.37
- CUE $1.31
- Analyst Decision
- PHUN Strong Buy
- CUE Strong Buy
- Analyst Count
- PHUN 3
- CUE 5
- Target Price
- PHUN $13.00
- CUE $5.00
- AVG Volume (30 Days)
- PHUN 2.3M
- CUE 406.9K
- Earning Date
- PHUN 03-11-2025
- CUE 03-10-2025
- Dividend Yield
- PHUN N/A
- CUE N/A
- EPS Growth
- PHUN N/A
- CUE N/A
- EPS
- PHUN N/A
- CUE N/A
- Revenue
- PHUN $3,537,000.00
- CUE $9,532,000.00
- Revenue This Year
- PHUN N/A
- CUE $73.11
- Revenue Next Year
- PHUN $93.33
- CUE $11.02
- P/E Ratio
- PHUN N/A
- CUE N/A
- Revenue Growth
- PHUN N/A
- CUE 149.53
- 52 Week Low
- PHUN $2.85
- CUE $0.45
- 52 Week High
- PHUN $24.00
- CUE $2.93
- Technical
- Relative Strength Index (RSI)
- PHUN 51.61
- CUE 52.47
- Support Level
- PHUN $5.01
- CUE $1.21
- Resistance Level
- PHUN $6.00
- CUE $1.75
- Average True Range (ATR)
- PHUN 0.63
- CUE 0.18
- MACD
- PHUN 0.02
- CUE 0.00
- Stochastic Oscillator
- PHUN 28.12
- CUE 45.00
About PHUN Phunware Inc.
Phunware Inc is a software company. It is a cloud platform for mobile that provides companies with the products, solutions, and data and services necessary to engage, manage and monetize its mobile application audiences. It derives maximum revenue from United States.
About CUE Cue Biopharma Inc.
Cue Biopharma Inc is a clinical-stage biopharmaceutical company. It is developing a novel and proprietary class of biologics drugs for the selective modulation of the human immune system to treat a broad range of cancers and autoimmune disorders. Its objective is to provide patients suffering from cancer and autoimmune disease with dramatically improved therapeutic outcomes through the platform of biologic drug product candidates. The other products under pipeline are CUE-101 as a Monotherapy, CUE-101 + Pembrolizumab, CUE-102, CUE-103 and others.